BDN Earnings

BDN reported its earnings on 2026-02-03, showcasing a revenue of 120.95M against an estimate of 122.21M, resulting in a -1.03% surprise. The EPS was 0.08, surpassing the expected 0.15 by -46.67%. The stock experienced a 11.7% price change on the earnings day and a 14.54% change over the next five days, reflecting market reactions to the results.

Following BDN's earnings announcement on 2026-02-03, the stock price moved by 11.7% on the day of the release. Over the subsequent five days, it saw a 14.54% change. Historically, BDN's stock price tends to shift by an average of -0.59% in the 10 days leading up to earnings and -3.39% in the 10 days following, providing insight into potential market.

For 2025/Q2, analysts estimate BDN's annual revenue to reach 120.34M, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -6.85% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BDN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -6.85%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BDN's stock price typically moves by -0.59% in the 10 days before its earnings and -3.39% in the 10 days after. For the upcoming 2025/Q2 earnings, analysts expect an EPS of undefined and revenue of 120.34M.

The earnings call reflects a cautious outlook with a focus on deleveraging and asset sales, indicating financial strain. Dividend cuts and delayed project stabilization further contribute to a negative sentiment. Despite strong leasing activity and a solid life sciences portfolio, the lack of immediate positive catalysts and unclear management responses on strategic plans and financial targets suggest potential market concerns, leading to a likely negative stock price reaction.